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INTRODUCTION 
 
Age-related macular degeneration (AMD) is the 
primary cause of irreversible vision loss among the 
ageing population worldwide. The number of people 
with AMD worldwide is expected to reach 196 million 
in 2020, increasing to 288 million in 2040 [1]. AMD is 
a degenerative and progressive disease involving 
multiple genetic and environmental factors, age being 
the primary risk factor.  
 
The retinal pigment epithelium (RPE) monolayer is 
believed to be among the initial targets of early disease. 
AMD presents RPE cell abnormalities, disruption of the 
outer blood-retinal-barrier (oBRB), and degeneration of 
photoreceptors, which require a normally functioning 
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ABSTRACT 
 
The retinal pigment epithelium (RPE) is considered one of the main targets of age-related macular degeneration 
(AMD), the leading cause of irreversible vision loss among the ageing population worldwide. Persistent low 
grade inflammation and oxidative stress eventually lead to RPE dysfunction and disruption of the outer blood-
retinal barrier (oBRB). Increased levels of circulating pentameric C-reactive protein (pCRP) are associated with 
higher risk of AMD. The monomeric form (mCRP) has been detected in drusen, the hallmark deposits associated 
with AMD, and we have found that mCRP induces oBRB disruption. However, it is unknown how mCRP is 
generated in the subretinal space. Using a Transwell model we found that both pCRP and mCRP can cross 
choroidal endothelial cells and reach the RPE in vitro and that mCRP, but not pCRP, is able to cross the RPE 
monolayer in ARPE-19 cells. Alternatively, mCRP can originate from the dissociation of pCRP in the surface of 
lipopolysaccharide-damaged RPE in both ARPE-19 and primary porcine RPE lines. In addition, we found that the 
proinflammatory phenotype of mCRP in the RPE depends on its topological localization. Together, our findings 
further support mCRP contribution to AMD progression enhancing oBRB disruption. 
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RPE to survive [2, 3]. Prior research has implicated 
strong roles for inflammation, oxidative stress, lipid 
abnormalities, and RPE dysfunction in AMD 
pathobiology, but their precise mechanisms and their 
relative contribution are unclear [4]. A multitude of 
systemic changes occur with ageing that contribute  
to the initiation and development of inflammation. 
Indeed, the immune system of elderly individuals is 
characterized by a basal systemic inflammatory state [5].  
 
Altered immune responses are thought to contribute to 
the dry AMD phenotype. Parainflammation is a low-
grade cytoprotective adaptation to local stress that is 
intermediate between immune-mediated homeostasis 
and chronic inflammation that maintains cellular and 
tissue function. Loss of parainflammation control 
contributes to AMD by invoking a chronic, heightened 
immune response that causes tissue destruction [6–8]. 
Histochemical and proteomic analysis of ocular drusen, 
the hallmark deposits of AMD, have shown that these 
deposits contain inflammatory proteins and complement 
components that mediate local inflammation [9, 10]. 
Furthermore, the strongest genetic risk factor for AMD 
known to date is a common polymorphism in the 
complement factor H (CFH) gene (c.1277T > C, 
p.Tyr402His), a gene essential for the regulation of 
complement activation [11, 12]. 
 
C-reactive protein (CRP), a prototypical acute-phase 
reactant, is an active regulator of the innate immune 
system. Among the multiple functions ascribed to CRP 
are activation of the classical complement pathway and 
inactivation of the alternative pathway [13]. CRP is 
considered to be a serum biomarker for chronic 
inflammation, heart disease and, more recently, also 
AMD [14, 15]. In plasma, CRP typically exists as a 
cyclic, disk-shaped pentamer (pentameric CRP, pCRP) 
composed of five noncovalently linked subunits of 23 
kDa [16]. However, pCRP can undergo dissociation into 
its subunits, acquiring distinct biological functions. 
Oxidative stress and bioactive lipids from activated or 
damaged cells can dissociate pCRP into its 23-kDa 
subunits [17–19] through a mechanism that is dependent 
on lysophosphatidylcholine (LPC) exposure after 
phospholipase A2 activation [20]. This alternative 
conformation of CRP, termed monomeric CRP (mCRP), 
has different antigenicity-expressing neoepitopes than 
pCRP and represents the tissue-based insoluble form of 
CRP. Unlike pCRP, mCRP displays a proinflammatory 
phenotype in several cell types [21–23].  
 
mCRP has been identified in ocular drusen and other 
subepithelial deposits [24, 25], as well as in the choroid, 
and we have shown that mCRP, but not pCRP, 
contributes to oBRB disruption in vitro [26]. Moreover, 
we also showed that the “non-risk” Factor H (FH) 
variant can effectively bind to mCRP to dampen mCRP 
pro-inflammatory activity [27]. Notably, FH from AMD 
patients carrying the risk polymorphism for AMD 
shows an impaired binding to mCRP and, therefore, its 
proinflammatory effects remain unrestrained [28]. In 
line with these findings, data demonstrates that mCRP 
is the more abundant form of CRP in human RPE-
choroid [29], and that mCRP levels are elevated in 
individuals with the high-risk CFH genotype [29, 30]. 
 
If mCRP pro-inflammatory capacity is unrestrained in 
AMD and particularly in high risk patients, then we 
need to determine how mCRP is generated or 
accumulates in the subretinal space as there is no CRP 
transcription in the retinal tissue [30, 31]. In addition, it 
is also unclear whether mCRP-induced barrier 
disruption depends on its topological localization.  
 
RESULTS 
 
Choroidal endothelial cells allow diffusion of CRP 
isoforms 
 
We first interrogated whether circulating CRP could 
reach the subretinal space using a Transwell model, in 
which confluent monolayers of primary porcine 
choroidal endothelial cells (CECs) were grown on 
porous filters with their apical and basolateral surfaces 
exposed to separate chambers (Figure 1A). Addition of 
mCRP to the apical chamber that mimics blood vessel 
lumen (A to B red arrow in Figure 1A) resulted in CRP 
diffusion into the basolateral chamber (tissue side) as 
Western blot (Figure 1B) and ELISA (Figure 1C) of the 
culture media of the different compartments revealed 
the presence of mCRP in both chambers. Similarly, 
pCRP was able to reach the abluminal side of the CEC 
monolayer, as seen by Western blot (Figure 1D). CRP 
isoforms were also able to reach the apical chamber 
when added in the abluminal compartment (B to A blue 
arrow in Figure 1A), suggesting bidirectional diffusion 
of the proteins. Immunofluorescence imaging showed 
that mCRP delivered to the apical compartment was 
extensively bound to the CEC surface compared to 
pCRP and to CRP (either mCRP or pCRP) delivered in 
the basolateral chamber (Figure 1E–1G).  
 
Diffusion of CRP across the RPE 
 
Given that CRP isoforms were able to cross the CEC 
monolayer in our in vitro model, we next evaluated 
whether CRP isoforms could also reach the subretinal 
space and cross the RPE, using the Transwell model. In 
this scenario the basolateral side of the RPE monolayer 
represents the Bruch’s membrane/choriocapillaris side, 
whereas the apical side represents the subretinal space 
(Figure 2A). Western blot experiments revealed that 
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Figure 1. CRP isoforms are able to cross CECs. (A) Experimental setup. CRP (10 µg/ml) was added to either the apical or basolateral 
chamber of the Transwell for 48h, mimicking blood vessel lumen and RPE, respectively. The presence of CRP in the opposite chamber where 
it was added was determined by Western blot and ELISA, and CRP bound to the cell surface was determined by immunofluorescence. (B) 
Western blot of mCRP present in apical (Up) and basolateral (Down) chamber (N=4). (C) ELISA of mCRP (ng/ml) from apical (Up) and 
basolateral (Down) supernatants. Values are expressed as mean ± SD (N=3). (D) Western-blot of pCRP present in apical (Up) and basolateral 
(Down) supernatants (N=5). (E) Immunofluorescence of CRP (red) stained with monoclonal antibodies against mCRP (3H12) or pCRP (1C6). 
Nuclei stained with DAPI. Scale bar = 50 µm (N=6). (F) Quantification of CRP binding measured as stained area divided by the number of cells 
per image (µm2/cell). Results are expressed as mean area (µm2/cell) ± SD. Statistical analysis was performed by One-Way ANOVA and Tukey’s 
posthoc. **P<0.01 vs. all conditions. (G) Reconstruction of x-z sections with a 0.3 µm z axis step of immunofluorescence images. Images 
shown are representative of six independent experiments. 
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mCRP was able to diffuse across ARPE-19 cell 
monolayer, as it was present in the apical chamber when 
added in the basolateral chamber (B to A, red arrow in 
Figure 2A). Diffusion of mCRP was greater at 48 hours 
compared to 24 hours (Figure 2B). We also detected the 
presence of mCRP by ELISA 48 hours after treatment 
in the opposite chamber where it was added (Figure 
2C). By contrast, pCRP did not seem to cross the 
ARPE-19 monolayer. Western blot experiments showed 
that pCRP was not present in the supernatant of the 
opposite chamber where it was added, neither at 24h nor 
at 48h after treatment (Figure 2D). Immunofluorescence 
imaging showed that mCRP delivered to the apical 
compartment was extensively bound to the ARPE-19 
cell monolayer compared to pCRP and to CRP (either 
mCRP or pCRP) delivered in the basolateral chamber 
(Figure 2E–2G).  
 
We then tested whether mCRP was also able to cross 
porcine primary RPE cells. Primary RPE cells represent 
a healthier and younger RPE than ARPE-19 cells, as 
they show more than 5 times higher TEER values 
(Supplementary Figure 1D, 1E). Interestingly, unlike 
ARPE-19 cells, primary porcine RPE cells did not allow 
mCRP diffusion as mCRP was not detected in the 
opposite chamber where it was added, neither in 
Western blot (Figure 3A) nor ELISA (Figure 3B). As 
expected, pCRP was also unable to cross the RPE 
monolayer (Figure 3C). Immunofluorescence imaging 
showed similar results to those with ARPE-19; mCRP 
delivered to the apical compartment was extensively 
bound to the RPE cell monolayer compared to pCRP 
and to CRP (either mCRP or pCRP) delivered in the 
basolateral chamber (Figure 3D–3F).  
 
Damaged RPE dissociates pCRP into mCRP 
 
Given that pCRP is able to cross the CEC monolayer and 
reach the subepithelial space in vitro, we next studied 
whether pCRP could dissociate into its monomeric 
subunits within the RPE. It has been previously described 
that LPS-induced inflammation induces CRP dissociation 
in the cremaster muscle [20], and therefore we studied 
whether LPS-induced inflammation could also lead to 
CRP dissociation in RPE cells. RPE cells were treated 
with 100 µg/mL LPS for 24h before adding pCRP. After 
24h, RPE cells were treated with pCRP for 48h and the 
presence of mCRP on the surface of RPE cells  
was measured by immunofluorescence. As observed in 
Figure 4, LPS-induced inflammation triggered pCRP 
dissociation into mCRP in both ARPE-19 (Figure 4A, 
4B) and primary porcine RPE cells (Figure 4C, 4D). 
Altogether these results show that mCRP present in 
drusen and in the subretinal space may either arrive from 
the choroidal circulation or it may originate from local 
dissociation of pCRP in damaged RPE. 
Topological localization of mCRP determines the 
impact on barrier disruption in RPE cells 
 
Next, we evaluated whether mCRP-induced barrier 
disruption depended on the topological localization of 
mCRP. For this purpose, ARPE-19 cells grown on 
inserts for at least 3 weeks were treated with CRP 
isoforms (10 µg/mL) either in the apical or basolateral 
compartment for 48h. As expected, mCRP delivered in 
the apical chamber, significantly decreased TEER 
values (Figure 5A). This observation was accompanied 
by an increase in paracellular permeability (Figure 5B) 
and an increased ZO-1 disorganization (Figure 5C, 5D, 
Supplementary Figure 3). Interestingly, abluminal 
treatment of mCRP also induced a significant decrease 
in TEER values. 
 
We then aimed to replicate the experiments in primary 
porcine RPE cells, which are less permeable to mCRP 
diffusion. As seen in Figure 6, apical treatment of 
mCRP, but not pCRP, induced barrier disruption also in 
primary RPE cells as seen by significant decrease in 
TEER (Figure 6A), increase in paracellular permeability 
(Figure 6B) and increased ZO-1 disorganization (Figure 
6C, 6D, Supplementary Figure 4). However, when 
mCRP was delivered into the abluminal compartment it 
failed to induce barrier disruption, showing that mCRP-
induced barrier disruption depends on its topological 
localization. 
 
DISCUSSION 
 
The present study aimed to understand the relative 
contribution of mCRP to the pathophysiology of AMD. 
Our in vitro work demonstrates that mCRP is capable of 
traversing through choroidal vascular endothelium and 
across RPE. Although no direct in vivo correlate, the 
data suggest that mCRP can reach the subretinal space. 
Alternatively, mCRP may derive from the dissociation 
of pCRP on the surface of damaged RPE. Moreover, we 
found that the proinflammatory phenotype of mCRP in 
the RPE depends on its topological localization. 
Together the data continues to build the evidence of 
mCRP accentuation of AMD pathology and detriment 
to RPE health. 
 
CRP is mainly produced in the liver and, although 
extrahepatic synthesis has been reported in some tissues, 
no evidence of CRP gene transcription has been detected 
in the retinal tissue [30, 31]. This indicates that the 
systemic circulation is the main source of CRP in the 
sub-RPE deposits. Indeed, we observed that both CRP 
isoforms, at clinically relevant concentrations, are able to 
cross CECs from their apical side -simulating blood 
side- and reach the basolateral side of the endothelium -
simulating the subepithelial side- in a Transwell model 
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Figure 2. Diffusion of CRP isoforms across ARPE-19 cells. (A) Experimental setup. CRP (10 µg/ml) was added to either the apical or 
basolateral chamber of Transwell for 48h, mimicking neural retina and choriocapillaris, respectively. The presence of CRP in the opposite 
chamber where it was added was determined by Western blot and ELISA, and CRP bound to the cell surface was determined by 
immunofluorescence. (B) Western blot of mCRP present in apical (Up) and basolateral (Down) supernatants after 24 and 48 hours of 
treatment (N=4). (C) ELISA of mCRP (ng/ml) from apical (Up) and basolateral (Down) supernatants 48 hours after treatment. Values are 
expressed as mean ± SD (N=3). (D) Western blot of pCRP present in apical (Up) and basolateral (Down) supernatants after 24 and 48 hours of 
treatment (N=4). (E) Immunofluorescence of CRP (red) stained with monoclonal antibodies against mCRP (3H12) or pCRP (1C6). Nuclei 
stained with DAPI. Scale bar = 50 µm (N=6). (F) Quantification of CRP binding measured as stained area divided by the number of cells per 
image (µm2/cell). Results are expressed as mean area (µm2/cell) ± SD. Statistical analysis was performed by One-Way ANOVA and Tukey’s 
posthoc. * P<0.05, ** P<0.01 vs. mCRP apical. (G) Reconstruction of x-z sections with a 0.3 µm z axis step of immunofluorescence images. 
Images shown are representative of six independent experiments. 
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Figure 3. Diffusion of CRP isoforms across primary porcine RPE cells. (A) Western blot of mCRP present in apical (Up) and basolateral 
(Down) supernatants 48 hours after addition of mCRP (N=4). (B) ELISA of mCRP (ng/ml) from apical (Up) and basolateral (Down) 
supernatants. Values are expressed as mean ± SD (N=5). (C) Western blot of pCRP present in apical (Up) and basolateral (Down) supernatants 
48 hours after treatment (N=3). (D) Immunofluorescence of CRP (red) stained with monoclonal antibodies against mCRP (3H12) or pCRP 
(1C6). Nuclei stained with DAPI. Scale bar = 30 µm (N=3). (E) Quantification of CRP binding measured as stained area divided by the number 
of cells per image (µm2/cell). Results are expressed as mean area (µm2/cell) ± SD. Statistical analysis was performed by One-Way ANOVA and 
Tukey’s posthoc. **P<0.01 vs. all conditions. (F) Reconstruction of x-z sections with a 0.3 µm z axis step of immunofluorescence images. 
Images shown are representative of three independent experiments. 
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(Figure 1). The choroidal endothelium is fenestrated, 
which allows the movement of macromolecules and 
nutrients to nourish the RPE cells [32]. Although mCRP 
could extravasate the endothelium and reach the 
subepithelial space, we observed by immunofluorescence 
that most mCRP was retained in the apical side of the 
endothelium. Indeed, mCRP promiscuously interacts 
with a variety of immunoglobulins and other proteins 
[33]. Thus, we tested whether mCRP in the subepithelial 
space could also originate from the dissociation of  
pCRP in the RPE. Using the approach of Thiele et al. 
[20], we found that LPS-induced inflammation lead to 
pCRP dissociation also in RPE cells (Figure 4). 
Mechanistically, this process is dependent on exposure 
of LPC, a bioactive lipid that is generated after 
phospholipase A2 activation on activated cell membranes 
[20]. Chirco et al. found that mCRP is predominantly 
localized in the choriocapillaris and Bruch´s membrane 
[29] and a previous work by Johnson and colleagues, 
looking at total CRP, showed that CRP was more 
abundant in donor eyes with the high-risk CFH 
polymorphism compared to age-matched controls, 
especially in regions containing drusen-like deposits 
[30]. A similar study compared differences in total CRP 
immunoreactivity in the retina based on AMD status and 
found that early and wet AMD eyes had higher levels of 
CRP compared to controls and that CRP was primarily 
detected into the BM [34]. In their work, Chirco et al. 
also showed that mCRP exerts an inflammatory effect on 
CEC, as it increases CEC migration and paracellular 
permeability and upregulates inflammatory gene 
expression including ICAM1, suggesting a role for 
mCRP in promoting inflammation in the choroid.  
 
Besides the proinflammatory effect in the choroid, we 
have previously demonstrated that clinically relevant 
concentrations of mCRP induce barrier disruption and 
have a proinflammatory effect in RPE in vitro and 
potential for driving angiogenesis [26, 27]. With respect 
to angiogenesis and neovessels, in the context of 
vascular disease, CRP inhibits VEGF production and 
angiogenesis [35, 36]. Conversely, others have shown 
CRP upregulates VEGF expression in adipose-derived 
stem cells and in monocytes [37, 38]. mCRP has been 
 
 
 
Figure 4. LPS-induced inflammation promotes CRP dissociation in RPE cells. RPE cells were treated with 100 µg/mL LPS for 24h 
before adding pCRP. After 24h, RPE cells were treated with pCRP for 48h and the presence of mCRP on the surface of RPE cells was measured 
by immunofluorescence. mCRP immunostaining of ARPE-19 (A) and primary porcine RPE (B) cells treated with 10 µg/ml mCRP for 48h (I, IV), 
25 µg/ml pCRP for 48h (II, V), or 100 µg/ml LPS 24h before treatment with 25 µg/ml pCRP for 48h (III, VI). Arrows point mCRP dissociated 
from pCRP on RPE surface. Nuclei stained with DAPI. Scale bar = 50 µm. Images shown are representative of three independent experiments. 
(C, D) Quantification of CRP dissociation measured as stained area with the monoclonal antibody 3H12 against mCRP (green) divided by the 
number of cells per image (µm2/cell). Results are expressed as mean area (µm2/cell) ± SD (N=3). Statistical analysis was performed by student 
t-test. *P<0.05 vs. pCRP. 
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localized around newly formed microvessels in carotid 
artery plaques and in peri-infarct regions after an acute 
ischemic stroke [39, 40], promoting angiogenesis and 
inducing inflammation [41]. One notion is understanding 
of mCRP role is context dependent and in vivo studies 
are required to determine the contribution of mCRP to 
neovessel formation in the context of AMD, either via 
VEGF dependent or -independent mechanisms. On the 
other hand, Lauer et al. showed that mCRP binds 
necrotic RPE cells and that complement regulation at 
necrotic cell lesions is impaired by the FH His402 risk 
variant [17]. In these studies, RPE cells were stimulated 
with mCRP from the apical side. However, given the 
polarized nature of RPE cells it could be possible that 
the proinflammatory effect of mCRP on RPE cells 
depends on its topological localization. Our results 
showed a polarized stimulation of mCRP on barrier 
disruption in RPE cells, in both ARPE-19 and primary 
porcine RPE cells. The addition of mCRP to the apical 
side of RPE cells resulted in a significantly greater 
barrier disruption -decreased TEER, increased 
permeability and disrupted membrane ZO-1- than the 
addition of mCRP to the basolateral side. This effect was 
more pronounced in primary RPE cells, where mCRP 
had no effect on barrier disruption when added from the 
basolateral side, than in ARPE-19 cells. Indeed, we 
observed by immunofluorescence a preferential binding 
of mCRP to the apical side (Figures 2, 3). The polarized 
proinflammatory effect of mCRP has been already 
observed in endothelial cells using a similar approach 
[42]. These observations could be due to a polarized 
distribution of the surface sensors for mCRP in the cell 
surface.  
 
The receptors that mediate mCRP activities have not 
been fully characterized. In human neutrophils, mCRP 
binds FcγRIII (CD16) [21]. However, functional 
blockade of CD16 showed only a slight attenuation of 
mCRP-induced activation in RPE and endothelial cells 
(ECs) [27, 43]. Instead, in ECs, lipid raft microdomains 
seem to be the major sensors for mCRP [44]. Therefore, 
it could be speculated that mCRP interacts with RPE 
cells through lipid raft microdomains. Nevertheless, 
unlike many other surface receptors in epithelial tissues, 
caveolae seem to have a bipolar distribution in RPE 
cells [45]. The increased immunoreactivity of mCRP 
when added to the apical side could be also attributed to 
the presence of the Transwell filter in the basolateral 
 
 
 
Figure 5. mCRP induces barrier disruption in ARPE-19 cells in a polarized manner. ARPE-19 cells were treated with CRP isoforms for 
48h either from the apical side or the basolateral chamber and TEER (A) and paracellular permeability as determined by FITC-dextran 
diffusion rate (B) was determined. (C) Cells were then fixed and immunostained with anti ZO-1 (red) and DAPI (blue). Images shown are 
representative of four independent experiments. Scale bar = 20 μm. (D) Quantification of ZO-1 at the TJs expressed as relative 
(intercellular/cytoplasmic) ZO-1 distribution. Values are expressed as mean ± SD and statistical analysis was performed by one-way ANOVA 
and Dunnett´s posthoc analysis (N=4). * P<0.05, ** P<0.01 vs. control. 
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side that could hamper the binding of mCRP to the 
basolateral side. This could also prevent mCRP to 
induce barrier disruption when added from the 
basolateral side. However, we used filters with a pore 
size of 0.4 μm, big enough to allow mCRP to reach the 
basolateral side of the RPE cells. It could be also 
possible that the receptors on the apical side of the cells 
have a greater affinity for mCRP than those in the 
basolateral side. However, we observed a similar 
pattern with different cell types (CEC, ARPE-19, and 
primary RPE), and therefore it is likely that our 
observations are mainly the consequence of mCRP 
settling on the cell surface.  
 
Given that mCRP seems to induce higher barrier 
disruption when present in the apical side of RPE cells, 
we tested whether mCRP could cross the RPE and reach 
the apical side when added in the basolateral side. RPE 
cells are critical for oBRB function, enabling selective 
transport of molecules in and out of the retina to 
preserve its immune privilege [7]. We found that pCRP 
was unable to reach the apical side -representing the 
subretinal space- of RPE cells. However, mCRP was 
able to reach the apical side only in ARPE-19 cells, but 
not in primary porcine RPE cells (Figures 2, 3). ARPE-
19, is a spontaneously arising RPE cell line that behaves 
in many ways like primary RPE cultures as they exhibit 
barrier functions mediated by tight junctions and secrete 
cytokines. However, they exhibit reduced TEER [46]. 
Indeed, ARPE-19 cells are commonly used for studying 
oxidative stress and cell signaling in AMD because they 
exhibit features of aged RPE [47]. Thus, the fact that 
ARPE-19 cells but not primary RPE cells allow mCRP 
diffusion to the apical side suggest that mCRP could 
reach the subretinal space when the RPE is damaged. 
These findings may explain why mCRP had some effect 
on barrier disruption on ARPE-19 cells but not in 
primary RPE cells when added from the basolateral 
side. As such, some mCRP may have crossed the 
ARPE-19 monolayer reaching the apical side, thereby 
inducing barrier disruption. 
 
Our current work suggests a plausible mechanism by 
which mCRP may contribute to RPE dysfunction and 
AMD progression: the serum-associated isoform of 
CRP (pCRP), would reach the oBRB by diffusion 
 
 
 
Figure 6. mCRP induces barrier disruption in primary porcine RPE cells in a polarized manner. Primary porcine RPE cells were 
treated with CRP isoforms for 48h either from the apical side or the basolateral chamber and TEER (A) and paracellular permeability as 
determined by FITC-dextran diffusion rate (B) was determined. (C) Cells were then fixed and immunostained with anti ZO-1 (red) and  
DAPI (blue). Images shown are representative of four independent experiments. Arrows show disruption of ZO-1. Scale bar = 20 μm.  
(D) Quantification of ZO-1 at the TJs expressed as relative (intercellular/cytoplasmic) ZO-1 distribution. Values are expressed as mean ± SD 
and statistical analysis was performed by one-way ANOVA and Dunnett´s posthoc analysis (N=6). * P<0.05, ** P<0.01, *** P<0.0001 vs. 
control. 
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through CECs from the choroidal circulation. Once 
there, it would undergo dissociation into mCRP via 
LPC exposed in RPE surface in an inflammatory 
microenvironment. Alternatively, mCRP could also be 
generated elsewhere -although in small amounts- or in 
the surface of CECs before reaching the oBRB. The 
mCRP in the subepithelial space could reach the apical 
side of a damaged RPE and amplify the inflammation 
further disrupting the RPE barrier integrity. 
 
The present work carries some limitations. Firstly, we 
used a simple model that did not incorporate a proper 
analogue of the Bruch’s membrane. We used 
fibronectin to grow CECs, laminin to grow primary 
porcine RPE cells, and ARPE-19 cells were grown 
without any protein coating in the Transwell filters. 
Secondly, we did not use RPE cells derived from 
inducible pluripotent stem cells which would have 
added more translatability to our work. However, we 
used two different models of RPE to understand how 
mCRP contributes to AMD progression, albeit in an in 
vitro setting. 
 
In summary, our findings further support mCRP direct 
contribution to progression of AMD, at least at the 
RPE level. The topological experiments elicit that 
mCRP is proinflammatory when present on the apical 
side of the RPE. However, mCRP is likely to only 
reach the apical side of the RPE in compromised RPE 
health and where barrier functions are compromised. 
Thus, a plausible scenario would infer that, in the 
presence of an already aged/damaged RPE, mCRP 
reaches the apical side of the RPE to amplify the 
proinflammatory microenvironment and enhance 
barrier disruption. With respect to previous findings, 
this pathologic mechanism will be more prevalent in 
patients carrying the FH risk polymorphism for AMD, 
where mCRP proinflammatory effects remain 
unrestrained [28].  
 
MATERIALS AND METHODS 
 
CRP isoforms 
 
High purity human pCRP (Calbiochem) was stored in 
10 mM Tris, 140 mM NaCl buffer (pH 8.0) containing 2 
mM CaCl2 to prevent spontaneous formation of mCRP 
from the native pentamer. mCRP was obtained by urea 
chelation from purified human CRP as previously 
described [23]. Briefly, pCRP at 1 mg/mL was chelated 
with 10 mM ethylene diaminetetraacetic acid (EDTA) 
and incubated in 8.0 M urea for 4 h at 37°C. Urea was 
removed via dialysis against low ionic strength TBS 
(0.01 M Tris-HCl and 0.05 M NaCl, pH 7.3). 
Monomeric CRP concentration was determined by the 
BCA protein assay. The filtered solution was stored at  
4 °C. pCRP was also dialyzed with TBS to remove 
sodium azide. 
 
Cell culture 
 
ARPE-19, a spontaneously arising human retinal pigment 
epithelium cell line, was obtained from the American 
Type Culture Collection (ATCC®CRL-2302™). ARPE-
19 (passages 15-20) were cultured in a 50:50 mixture of 
Dulbecco modified Eagle medium (DMEM) and Ham’s 
F12 (Biowest) supplemented with 10% fetal bovine 
serum (FBS, Biowest), 2 mM L-glutamine (Biowest), 
100 U/mL penicillin (PAA), 0.1 mg/mL streptomycin 
(Biowest), and 1mM sodium pyruvate (Sigma) in a 
humidified incubator at 37°C in 5% CO2. Cells were 
passed every 4 to 6 days by trypsinization. ARPE-19 
cells were plated at confluence onto semi-permeable 
polycarbonate Transwell® filters, 0.4 μm pore size. At 
day 3 FBS was reduced to 2 % and cells were maintained 
in a 37°C and 5% CO2 incubator for 2–4 weeks, 
changing media every 3–4 days. 
 
Primary porcine RPE cells were isolated and cultured 
following the protocol described by [48] with some 
modifications. Eyes were trimmed of excess tissue and 
placed in 0.2% povidone iodine for 10 minutes on ice. 
Eyes were rinsed with sterile distilled water and placed 
in 1000 U/mL Penicillin-Streptomycin on ice for a 
minimum of 5 minutes. Anterior segments were 
removed with a scalpel at the ora serrata. Eyecups were 
filled with 1 mM EDTA and incubated at 37°C for 30 
minutes to loosen the neural retina from the RPE sheet. 
The retina was gently pulled and detached from the 
RPE sheet. RPE cells were collected after incubation of 
the eyecups with 0.05% trypsin with 0.67 mM EDTA at 
37°C. After trypsin inactivation with 10% FBS, RPE 
suspension was centrifuged and plated in DMEM High 
Glucose (Capricorn Scientific), with L-glutamine and 
sodium pyruvate, supplemented with 1% penicillin-
streptomycin, 1% non-essential amino acids (Corning) 
and 10% FBS. At day 3 of culture, 5 µg/ml of 
ciprofloxacin (Sigma) was added to the medium and at 
day 7, serum was decreased to 1%. Cell monolayers 
were pigmented and showed the characteristic 
cobblestone morphology. At day 14, RPE cells were 
trypsinized and plated at confluence onto semi-
permeable polycarbonate Transwell® filters, 0.4 μm 
pore size, previously coated with laminin. RPE cells 
were maintained in a 37°C and 5% CO2 incubator for 
2–4 weeks and fed with 1% FBS growth medium every 
3–4 days. These RPE cells expressed RPE-specific 
markers and showed high levels of TEER (see 
Supplementary Figure 1). 
 
Choroidal endothelial cells from porcine eyes were 
isolated and cultured as described by Browning et al. [49] 
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with few modifications. Briefly, after the retina and RPE 
cell layer were removed with a cell scraper, the complex 
choroid-Bruch’s membrane was peeled off from the 
sclera, cut into small pieces and washed three times with 
Minimum Essential Medium (MEM, ThermoFisher). The 
pieces were incubated with 0.1% collagenase (Sigma) for 
2 hours at 37°C. The collagenase was neutralized with 
MEM containing 10% FBS and the mixture was passed 
through a 20G syringe. After centrifugation and washing 
with isolation medium, cells were resuspended in 0.1% 
BSA-PBS, adjusted to 1 x 107 cells/ml, and incubated 
with rabbit anti-CD31 (Abcam) (20 µl per ml of cell 
suspension) for 1 hour at room temperature (RT) with 
agitation. Cells were centrifuged, washed with PBS and 
incubated with Dynabeads® for 45 minutes at 4°C. 
Endothelial cells positively selected were resuspended in 
EGM-MV2 (PromoCell) without hydrocortisone and 
seeded onto 0.5% gelatin coated wells. CECs expressed 
characteristic endothelial markers (CD31, and VWF) and 
showed the capacity of endothelial tube formation for up 
to passage 8 (see Supplementary Figure 2). CECs were 
plated at confluence onto semi-permeable polycarbonate 
Transwell® filters, 0.4 μm pore size, previously coated 
with 10 µg/mL fibronectin and maintained at 37°C and 
5% CO2 incubator in EGM-MV2 media (Promocell). 
 
Measurement of transepithelial electrical resistance 
(TEER) 
 
TEER was measured using a commercial electrical 
resistance system (Millicell; Millipore) in ARPE-19 and 
primary porcine RPE monolayers grown on Transwell 
filters as described above. TEER values were calculated 
by subtracting the value of a blank (transwell filter 
without cells). Measurements were repeated at least 
three times for each filter, and each experiment was 
repeated at least five times using 2 filters. 
 
Permeability assay 
 
The paracellular permeability of ARPE-19 and primary 
porcine RPE monolayers was assessed by measuring the 
passive permeation of FITC-dextran (40 kDa, Sigma-
Aldrich) across confluent cells grown on filters for a 
minimum of 3 weeks. Then, the RPE monolayers were 
treated with CRP isoforms (10 μg/mL) for 48h. After 
48h treatment, 500 μg/ml FITC-dextran were added to 
the apical compartment of the chamber and samples (200 
μl) from the basal medium (lower chamber) were 
collected 120 min after addition of FITC-dextran. The 
absorbance of basal and apical medium samples was 
measured at 485 nm of excitation and 528 nm of 
emission in a microplate reader (Infinite 200 PRO 
multimode, Tecan Group Ltd., Switzerland). Each 
condition was assayed in triplicate and repeated in at 
least five independent experiments. The diffusion rate 
was expressed as a percentage and calculated as follows: 
(amount of dextran lower chamber) x100 / (amount of 
dextran upper chamber).  
 
Immunofluorescence 
 
The distribution of ZO-1 and RPE65 in RPE monolayers, 
CD31 and VWF expression in CECs, and CRP binding to 
RPE and CECs was examined by immunofluorescence. 
Filters were cut out, washed with PBS and fixed with 
3.8% paraformaldehyde in PBS for 15 min at room 
temperature (RT). Cells were then washed with PBS, 
permeabilized with Triton X-100 (0.2% for ZO-1 and 
CD31, and 0.5 % for RPE65) for 15 minutes and blocked 
twice with filtered 1% BSA. Cells were then incubated 
with primary antibody anti-ZO-1 (clone 1A12, Thermo 
Scientific), anti-RPE65 (clone 401.8B11.3D9, Abcam), 
anti-CD31 (Abcam), anti-mCRP (3H12 gently provided 
by Dr LA Potempa) or anti-pCRP (1D6, gently provided 
by Dr LA Potempa) overnight. After washing three times 
with PBS, cells were incubated with secondary antibody 
Alexa Fluor anti-mouse 488 or 568 IgG or anti-rabbit 568 
IgG for 1h at RT. Nuclei were counterstained with DAPI. 
Controls were stained with secondary antibodies only. 
Stained cells were washed and covered with Prolong 
Gold antifade reagent (Life Technologies). Images of 
immunostained cells were recorded on the high-speed 
spectral confocal microscope Leica TCS-SP5 and 
analyzed with ImageJ software. ZO-1 was intensity at the 
tight junctions (TJs) was measured as intensity at the 
intercellular junction divided by the intensity at the 
cytoplasm [50]. 
 
SDS-PAGE and immunoblotting 
 
The presence of CRP isoforms on apical and basolateral 
compartments was detected by SDS-PAGE and 
immunoblotting. Supernatants were centrifuged at 1,000 
g for 10 minutes, loaded onto 12.5% polyacrylamide 
gels and run at 30 mA for 60 minutes. In order to avoid 
denaturalization of pCRP, samples were not heated and 
the amount of SDS in the acrylamide gels and the 
loading and electrophoresis buffers was reduced to 1/20 
[51]. Proteins were transferred to a 0.22 µm 
nitrocellulose membrane performing a semi-dry transfer 
protocol. Non-specific binding sites were blocked with 
5% non-fat dry milk in 0.1% PBS-Tween for 1 hour at 
RT, before incubation with anti-mCRP-specific 
monoclonal antibody 3H12 1:300 in blocking buffer 
ON at 4°C. Membranes were incubated with the 
secondary antibody linked to HRP (GAM-HRP, Bio-
Rad) for 1 hour at RT. Chemiluminescent signal was 
detected with the Amersham ECL™ Prime Western 
blotting detection reagent (GE Healthcare) with 
ImageQuant LAS4000 (GE Healthcare) and bands were 
analyzed using ImageJ software. 
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Determination of mCRP in cell supernatants 
 
mCRP was detected in cellular supernatants (previously 
centrifuged at 1,000 g for 10 min) by an ELISA assay 
following the protocol recently described by Zhang et al. 
[52]. For this purpose, mouse anti-human CRP mAb 
CRP-8 (Sigma-Aldrich, C1688) was immobilized as 
capture antibody at 1:1,000 in coating buffer (10 mM 
sodium carbonate/bicarbonate, pH 9.6) overnight at 4°C. 
After washing three times for 2 minutes each with TBS, 
non-specific binding sites were blocked with filtered 1% 
BSA-TBS for 1 hour at RT. Samples diluted 1:100 in 
blocking buffer were added into wells for 1 hour at RT. 
Then, washing step was repeated and samples were 
incubated with sheep anti-human CRP polyclonal 
antibody (1:2,000 in blocking buffer) (BindingSite), prior 
incubation with a HRP-labeled donkey anti-sheep IgG 
(1:10,000 in blocking buffer) (Abcam). Signaling was 
detected with VersaMax Microplate Reader and The OD 
value of each sample was calculated as OD450–OD570 nm. 
 
Statistical analysis 
 
Results were expressed as mean ± SD. Student’s t test or 
ANOVA followed by Dunnett’s posthoc analysis were 
used to determine statistical significance between 
treatments. A value of P<0.05 was considered significant. 
All calculations were performed using GraphPad Prism 
(GraphPad Software, San Diego, CA, USA). 
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SUPPLEMENTARY MATERIALS 
 
Supplementary Figures 
 
 
 
Supplementary Figure 1. Characterization of RPE cells. (A) Cells harvested for 1, 7 and 14 days after plating. Objective lens 10x. 
Primary porcine RPE cells cultured for 30 days were stained with antibodies to RPE65 (green) (B) and ZO-1 (red) (C). Scale bar = 20 µm.  
(D) TEER values of primary porcine RPE cells plated at 280,000 cells/cm2 on laminin coated Transwell™ filters. (E) TEER values of ARPE-19 cells 
plated at 250,000 cells/cm2 on Transwell™ filters for 35 days. 
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Supplementary Figure 2. Characterization of primary porcine CECs. (A) Primary porcine CECs were cultured into pure matrigel-
coated wells and allowed to form capillary-like structures for 24 hours. Scale bar = 500 µm. Primary porcine CECs were stained with 
antibodies against CD31 (B) and VWF (C). Scale bar = 20 µm. (D) Negative control with cells stained without primary antibody. 
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Supplementary Figure 3. Effect of CRP isoforms on ZO-1 expression in ARPE-19 cells. Cells were fixed and immunostained with anti 
ZO-1 (red) and DAPI (blue). Scale bar = 30 μm. 
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Supplementary Figure 4. Effect of CRP isoforms on ZO-1 expression in primary porcine RPE cells. Cells were fixed and 
immunostained with anti ZO-1 (red) and DAPI (blue). Scale bar = 30 μm. 
